Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 31-40 of 400 for multiple

Edit search filters
  1. A Study to Evaluate Mesenchymal Stem Cells to Treat Multiple System Atrophy

    Rochester, MN

  2. FT576 in Subjects With Multiple Myeloma

    Jacksonville, FL

  3. A Study of BHV-3241 in Subjects with Multiple System Atrophy

    Rochester, MN

  4. A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants with Smoldering Multiple Myeloma

    Jacksonville, FL

  5. Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  6. A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma

    Scottsdale/Phoenix, AZ

  7. A Study of SAR442085 in Relapsed or Refractory Multiple Myeloma

    Rochester, MN

  8. A Study to Evaluate the Safety and Effectiveness of Metformin and Nelfinavir with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma

    Jacksonville, FL, Rochester, MN

  9. Cyclophosphamide, Ixazomib, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

    Scottsdale/Phoenix, AZ, Rochester, MN

  10. A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer